GlassScriptPhysician profile
Eliathamby Kuganeswaran
NPI 1073555488
$7,439.53
in general payments reported to CMS, 2019-2025
34 companies · $1,871 in 2025
The $1,871 reported for 2025 was more than what 77% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $588 · 2020: $346 · 2021: $923 · 2022: $932 · 2023: $1,433 · 2024: $1,346 · 2025: $1,871.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,544 · Education: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,544.36 |
| Education | $105.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,631.71 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $827.86 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $621.76 | 2021-2025 | Stelara, Tremfya, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $361.34 | 2019-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $335.32 | 2019-2024 | Dificid, Zinplava |
| Celgene Corporation | $284.74 | 2021-2024 | Zeposia |
| Gilead Sciences, INC. | $157.70 | 2022-2025 | |
| Madrigal Pharmaceuticals | $126.65 | 2024-2025 | Rezdiffra, Resmetirom |
| Nestle Healthcare Nutrition INC. | $122.74 | 2020-2023 | |
| Pfizer INC. | $122.11 | 2019-2021 | |
| Ardelyx, INC. | $117.55 | 2023-2025 | Ibsrela |
| Lilly USA, LLC | $82.73 | 2024-2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $70.92 | 2024-2025 | Voquezna |
| Ucb, INC. | $69.60 | 2019-2020 | |
| Allergan, INC. | $67.15 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $61.36 | 2021-2024 | |
| Amgen INC. | $52.76 | 2023 | Amjevita, Avsola |
| Aimmune Therapeutics, INC. | $44.49 | 2025 | Zenpep |
| Orphalan INC | $33.34 | 2025 | Cuvrior |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.29 | 2023 | Cyltezo |
| Ferring Pharmaceuticals INC. | $29.81 | 2025 | Rebyota |
| Celltrion USA INC. | $27.59 | 2025 | Vegzelma |
| Ipsen Biopharmaceuticals, INC | $19.83 | 2025 | Iqirvo |
| Ethicon US, LLC | $18.25 | 2019 | |
| Organon LLC | $17.97 | 2021 | |
| Qol Medical, LLC | $15.18 | 2025 | Sucraid |
| Digestive Care, INC. | $14.26 | 2025 | Pertzye |
| Mallinckrodt Hospital Products INC. | $14.08 | 2025 | Terlivaz |
| Intercept Pharmaceuticals, INC. | $13.74 | 2020 | |
| Amag Pharmaceuticals, INC. | $12.68 | 2021 | |
| Alfasigma USA, INC. | $12.00 | 2020 | |
| Genzyme Corporation | $11.78 | 2019 | |
| Janssen Pharmaceuticals, INC | $9.24 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$19,987.16 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eliathamby Kuganeswaran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.